阿昔莫司、洛伐他汀治疗老年混合型高脂血症随机对照研究  

The efficacy and safety comparison of acipimox,lovastatin in treatment on aged people with combined hyperlipidemia

作　　者：郭文萃[1] 高颖昌[1] 冯伟捷[1] 

机构地区：[1]北京天坛医院,北京100050

出　　处：《山东医药》2006年第28期16-17,共2页Shandong Medical Journal

摘　　要：目的比较烟酸衍生物阿昔莫司、他汀类药物洛伐他汀单独应用及两者联用治疗老年混合型高脂血症的疗效与安全性。方法106例混合型高脂血症患者随机分为三组。洛伐他汀组36例,给予洛伐他汀20 m g/d;阿昔莫司组37例,给予阿昔莫司750 m g/d;联合组33例,给予洛伐他汀20 m g/d、阿昔莫司750 m g/d。治疗8周,观察降脂疗效、不良反应。结果降总胆固醇、低密度脂蛋白胆固醇效果洛伐他汀组优于阿昔莫司组及联用组。降甘油三酯、动脉硬化指数及升高高密度脂蛋白胆固醇效果联用组最好。结论治疗老年混合型高血脂症可首选他汀类药物,必要时与烟酸类药物联用,全面调节血脂参数达标。[Objective] To evaluate the efficacy and safety of acipimox, lovastatin with either drug alone or combined in treatment on aged people with combined hyperlipidemia. [Methods] A total of 106 patients with combined hyperlipidemia were randomly divided into 3 groups, of which lovastatin 20 mg/d for 8 weeks in 36 cases, acipimox 750 mg/d for 8 weeks in 37 cases, lovastatin 20 mg/d with acipimox 750 mg/d for 8 weeks in 33 cases. [Results] Lovastation was superior to acipimox and acipimox＋lovastation in reduction of TC and LDL-C. Acipimox ＋lovastation is best in elevation of HDL-C and in reduction of （TC--HDL-C）/HDL-C. [Conclusion] In general, the statins should be the first option, and then acipimox could be supplemented when it is necessary in treatment of combined hyperlipidemia.

关 键 词：阿昔莫司 洛伐他汀 高脂蛋白血症 Ⅴ型 

分 类 号：R589.2[医药卫生—内分泌]